Advertisement

Picture EBD Group BioPharm America 2018 Boston September 600x60px
Document › Details

AstraZeneca plc. (7/27/17). "Press Release: H1 2017 Results".

Organisation Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
Products Product Imfinzi®
  Product 2 Lynparza®
Person Person Soriot, Pascal (AstraZeneca 201210– CEO before Roche COO Pharma Div before Genentech CEO)
     


Pascal Soriot, Chief Executive Officer, commenting on the results said:

“Our performance in the first half was in line with expectations as we experience the loss of exclusivity of Crestor and Seroquel XR in the US. We continued to deliver transformative science across the pipeline, particularly in Oncology. Imfinzi was launched in bladder cancer while we published practice-changing data in breast cancer for Lynparza, our first-in-class PARP inhibitor. In lung cancer, we strengthened our unique portfolio focused on both the genetic drivers of disease and immunotherapy. In the first half, we shared positive results for Imfinzi in the PACIFIC trial and reported more encouraging data for Tagrisso in patients with central nervous system metastases.

“I’m excited about our pipeline-driven transformation as we continue to deliver for shareholders on our strategy to return to sustainable long-term growth. In a pivotal year for AstraZeneca, we remain focused on realising the potential of our pipeline, growing our new launch medicines and bringing our strong science to patients.”


Downloads
H1 2017 Results announcement (PDF 2.1mb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/H1/H1_2017_Results_announcement.pdf ]

H1 2017 Results presentation (PDF 1.4mb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/H1/H1_2017_Results_Presentation.pdf ]

H1 2017 Results Clinical trials appendix (PDF 2.5mb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/H1/H1_2017_Results_Clinical_Trial_Appendix.pdf ]

H1 2017 Results Transcript (PDF 220kb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/H1/H1_2017_Results_transcript.pdf ]

   
Record changed: 2017-08-02

Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 600x80px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px




» top